Monitoring Agency Report

August 14, 2026 The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400051 Dear Sir/ Madam, Trading Symbol: ZOTA Sub: Monitoring Agency Report issued by CRISIL Ratings Limited for the utilization of funds raised through Qualified Institutional Placement for quarter ended June 30, 2026 Ref: Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018; we, Zota Health Care Limited, have enclosed herewith the Monitoring Agency Report issued by the CRISIL Ratings Limited, Monitoring Agency, appointed by the Company for monitoring the utilization of funds raised through Qualified Institutional Placement as approved by the Board and members of the Company in their respective meetings held on September 04, 2025 and September 29, 2025, for the quarter ended on June 30, 2026. The above Monitoring agency report has been reviewed by the Audit committee and Board of Directors of the Company in their respective meetings held on August 13, 2026. This is for your information and record. Thanking you, Yours faithfully, For Zota Health Care Limited Ashvin Variya (Group Company Secretary & Compliance Officer) Place: Surat Encl.: a/a Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352 Monitoring Agency Report Zota Health Care Limited for the quarter ended June 30, 2026 CRL/MAR/ZHCL/2026-27/1965 August 14, 2026 Zota Health Care Limited Zota House 2/896, Hira Modi Street, Sagrampura, Surat, Gujarat-395002 Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Qualified Institutional Placement (“QIP”) of Zota Health Care Limited (“the Company”) Pursuant to Regulation 173A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated December 15, 2025 enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of QIP for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Report of the Monitoring Agency (MA) Name of the issuer: Zota Health Care Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Not applicable (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Zota Health Care Limited Names of the promoter: Mr. Kamlesh Rajnikant Zota Mr. Ketankumar Chandulal Zota Mr. Manukant Chandulal Zota Mr. Himanshubhai Muktilal Zota Industry/sector to which it belongs: Pharmaceuticals 2) Issue Details Issue Period: December 15, 2025, to December 17, 2025 Type of issue (public/rights): Qualified Institutional Placement (QIP) Type of specified securities: Equity Shares QIP Grading, if any: Not applicable Issue size: Rs 34,999.99 lakh (Net proceeds: Rs 34,033.24 lakh) * *Crisil Ratings shall be monitoring the net proceeds amount. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ certifications Comments considered by Comments of the Particulars Reply of the Board Monitoring Agency Monitoring Agency of Directors for preparation of report Statutory Auditor Certificate^, The company has Management utilized proceeds for undertaking, funding working Placement Document capital requirements, Whether all utilization is as per the No Yes dated December 17, investment in DHML disclosures in the Offer Document? comments 2025 (hereinafter for setting up new referred to as COCO stores and “Placement General Corporate Document), Bank Purpose Statements Whether shareholder approval has been Statutory Auditor obtained in case of material deviations Certificate^, No NA No comments from expenditures disclosed in the Offer Management comments Document? undertaking Source of information/ certifications Comments considered by Comments of the Particulars Reply of the Board Monitoring Agency Monitoring Agency of Directors for preparation of report Whether the means of finance for the disclosed objects of the issue has No No comments comments changed? Is there any major deviation observed over the earlier monitoring agency NA No comments comments reports? Whether all Government/statutory Statutory Auditor approvals related to the object(s) have NA No comments Certificate^, comments been obtained? Management Undertaking Whether all arrangements pertaining to technical assistance/collaboration are in NA No comments comments operation? Are there any favorable events improving the viability of these No No comments comments object(s)? Are there any unfavorable events No No No comments affecting the viability of the object(s)? comments Is there any other relevant information that may materially affect the decision No No comments comments making of the investors? NA represents Not Applicable ^Certificate dated August 08, 2026, issued by M/s Pradeep K. Singhi & Associates, Chartered Accountants (Firm Registration Number: 0126027W), Statutory Auditors of the Company 4) Details of object(s) to be monitored: i. Cost of the object(s): Source of Original Comments of the Board of Directors information/ cost Revised Comments certification (as per the Particulars of Sr. Cost of the Reason Proposed Item considered by Offer firm arrange- No. (Rs in Monitoring of Cost financing Head MA for Document) ments l [Showing first 8,000 characters — download PDF for full document]